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LETTER TO THE EDITOR
The microenvironment of classical Hodgkin lymphoma:
heterogeneity by Epstein–Barr virus presence and
location within the tumor
Blood Cancer Journal (2016) 6, e417; doi:10.1038/bcj.2016.26;
published online 6 May 2016
Classical Hodgkin lymphoma (cHL) is characterized by a low
number of malignant cells, called Hodgkin Reed–Sternberg
(HRS) cells, surrounded by an abundant inﬁltrate of immune cells.
Presence of T helper (Th)2 and regulatory T cells (Treg) in the inﬁ-
ltrate was shown by staining of T-cell subtype speciﬁc transcrip-
tion factors in cHL tissue samples1 and by expression of Th2- and
Treg-speciﬁc cytokines in sorted T-cell subsets.2 However, one
study revealed a predominant Th1 subpopulation in the micro-
environment of cHL based on expression of CXCR3 by ﬂow
cytometry.3 Differences between these studies may potentially be
explained by heterogeneity between Epstein–Barr virus (EBV)-
positive and -negative cHL cases and by differences in cell
composition in relation to proximity of tumor cells.
In this study, we compared the composition of the reactive
inﬁltrate of EBV+ (n= 7) and EBV− cHL (n= 7) with each other and
with reactive lymph nodes (RLNs) for 46 speciﬁc cell types
(Supplementary Table S1). In addition, we made a distinction
between cells that are located in the close vicinity of tumor cells
and cells that are further away. The characteristics of the study
cohort has been described in Table 1. The gender distribution and
age range of the HL patients are comparable with the RLN cohort.
There is no signiﬁcant difference in ages between the EBV+ and
EBV− patients. The majority of the HL patients have nodular
sclerosis (NS) histology, within the EBV+ cHL group relatively more
mixed cellularity (MC) cases are found.
We did not ﬁnd any signiﬁcant differences between HL and RLN
in the main cell populations (B cells, T cells, natural killer (NK) cells
and macrophages)(Supplementary Table S2). In contrast to
previous studies using immunohistochemistry (range 3–57%),4
we observed relatively low percentages of macrophages.
This might be caused by a less optimal isolation of macrophages
from fresh tissues, resulting in an underrepresentation of these
cells in our ﬂow analysis.
Analysis of different T-cell subpopulations revealed signiﬁcantly
more GITR+CD25+ and FoxP3+CD25+ Treg cells in the CD4+ T-cell
subset in both EBV+ and EBV− cHL compared with RLNs
(Figures 1a and b). This increase in Treg cells is consistent with a
previously published study.5 We observed no signiﬁcant differ-
ence for EBV+ and EBV− cHL in the percentage of Tregs,
suggesting that suppression of the immune response is important
in both EBV+ and EBV− cHL. FoxP3+CD25+CD4+ Tregs
were upregulated in EBV+ HL cases by immunohistochemistry.6
Moreover, upregulation of messenger RNA (mRNA) levels for Treg-
associated markers and cytokines has also been described in EBV+
cHL compared with RLN and EBV− cHL, especially for T regulatory
1 cells, that produce interleukin-10.7 Together these ﬁndings
indicate that Tregs are important in all cHL cases, albeit more
pronounced in the microenvironment of EBV+ HL.
The percentage of CD56+CD16+ NK cells was signiﬁcantly lower
in EBV− cHL compared with RLN and EBV+ cHL (Figure 1c).
In addition, we observed signiﬁcantly more CD69+, granzyme
B+ and TIA-1+ cells in the CD8+ T-cell subset in EBV+ cHL
compared with RLN and EBV− cHL (Figures 1d–f). Thus, EBV status
has a positive correlation with the percentage of NK cells and
activated CD8+ T cells. This suggests that the presentation of EBV-
derived antigenic peptides within human leucocyte antigen class I
molecules triggers antiviral immune responses. The number of NK
cells can increase upon recognition of virus by toll-like receptors.
The higher numbers of cytotoxic CD8+ T cells in EBV+ cHL
indicates a Th1 response as Th1 cells stimulate a cellular-immune
response and activate CD8+ T cells. In contrast to the ﬁndings of
Greaves et al.,3 we did not ﬁnd signiﬁcant increases in the
percentage of CXCR3+ Th1 cells within the CD4+ cells in either
EBV+ or in EBV− cHL.
The combined presence of Tregs and activated CD8+ T cells
raises the questions on how they can coexist in cHL and where
they are located in respect to the tumor cells. To answer these
questions, we used CD26 to discriminate between T cells in the
area of the HRS cells, that is, the CD26− T cells, and the T cells that
are not in close contact with the HRS cells, that is, the CD26+ T
cells.2 To conﬁrm the relevance of using CD26 as a marker,
Table 1. Characteristics of the study cohorts
Clinical characteristics RLN N= 7 All cHL N= 14 EBV+ cHL N= 7 EBV− cHL N= 7 P-value
Gender
Male (%) 4 (57) 7 (50) 5 (71) 2 (29) ns
Age
Mean (range) 43 (17–72) 36 (12–76) 42 (12–76) 29 (13–54) ns
Histology subtype
NS (%) — 8 (57) 3 (43) 5 (72)
MC (%) — 3 (21) 3 (43) 0 ns
LR (%) — 2 (14) 1 (14) 1 (14)
NOS (%) — 1 (7) 0 1 (14)
Abbreviations: cHL, classical Hodgkin lymphoma; EBV, Epstein–Barr virus; LR, lymphocyte-rich; MC, mixed cellularity; N, number; NOS, not otherwise speciﬁed;
ns, not signiﬁcant; NS, nodular sclerosis; RLN, reactive lymph node. Mann–Whitney U test was used to compare the differences between EBV+ cHL with
EBV− cHL.
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we ﬁrst stained CD26 in the cHL tissue sections. In the NS and
lymphocyte-rich subtypes of cHL, CD26− cells were indeed
located in the close vicinity of tumor cells, whereas CD26+ cells
were not observed in the tumor cell areas. In MC, the CD26+ cells
were much more dispersed and were also found close to the
tumor cells. Based on these staining results, we excluded the MC
cases from the subsequent analyses.
We found signiﬁcantly more CD69+ Th cells in the CD26− T-cell
subset indicating that these cells are more abundant in the tumor
cell area (Figure 1g). This suggests triggering of an immune reaction
in these cells because CD69 is an early activation marker. A similar
pattern was observed in EBV+ as well as EBV− cHL. Furthermore, we
also observed more FoxP3+-suppressive Th cells in the tumor cell
area in both EBV+ and EBV− cHL (Figure 1h). These ﬁndings are
consistent with increased mRNA levels of Treg-associated genes
(CTLA4, IL2RA, TNFRSF4 and CCR4) in CD4+CD26− T cells in cHL
compared with RLN.2 So, the Tregs reside in the direct vicinity of the
HRS cells and might inhibit an effective antitumor immune response.
There were less CD25+ CD8+ cells around the tumor cells than
outside the tumor cell area (Figure 1i). So, although activated
CD8+ cells are present in the microenvironment of cHL, these cells
are not present in the tumor-cell-rich areas and thus not effective.
In conclusion, we showed that the main difference in the
composition of the microenvironment between EBV+ and EBV−
cHL patients is caused by increased numbers of both CD8+ T cells
and NK cells. High numbers of CD4+ Tregs directly surrounding
HRS cells imply that they have an important role in the failure to
induce an effective immune response against the HRS cells of cHL.
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Figure 1. Signiﬁcantly different immune cell populations in cHL. Optimized concentrations of ﬂuorochrome-antibody conjugates were applied
on cell suspensions of cHL tissue and analyzed by ﬂow cytometry. (a–f) Signiﬁcant differences in immune cell populations between RLN and
EBV+ and EBV− cHL. Percentages of (a) GITR+CD25+ in CD4+ cells; (b) FoxP3+CD25+ in CD4+ cells; (c) CD16+ in CD56+ cells; (d) CD69+ in
CD8+ cells; (e) Granzyme B+ in CD8+ cells; (f) TIA-1+ in CD8+ cells. An overview of all subsets tested and of all results has been given in
Supplementary Tables S1–3. Lines indicate the median percentage of each group. Kruskal–Wallis test was used to test for differences in all
three groups and a P-value of 0.0125 (to correct for multiple testing) was considered to be signiﬁcant. Mann–Whitney U test was used as a post
hoc test to identify signiﬁcant differences in groups. (*Po0.05; **Po0.01). (g–i) Cell populations with signiﬁcant differences between CD26−
and CD26+ T cells in cHL overall and EBV-stratiﬁed subgroups. (g) Percentages of CD69+ in CD4+ cells in cHL; (h) FoxP3+ in CD4+ cells in cHL;
(i) CD25+ in CD8+ cells in cHL. Lines indicate the median percentage of each group. Wilcoxon-matched-pairs signed-rank test was used to
compare the two groups.
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